Palvella Therapeutics (PVLA) Debt Ratio (2013 - 2025)
Palvella Therapeutics (PVLA) posted quarterly Debt Ratio of 0.06 for Q4 2014, down 74.39% year-over-year from 0.23 in Q4 2013, and down 99.68% quarter-over-quarter from 17.95 in Q3 2014.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Debt Ratio (2013 - 2025) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Debt Ratio for 2 consecutive years, with 0.06 the latest figure, recorded in Q4 2014.
- In Q4 2014, Debt Ratio fell 74.39% year-over-year to 0.06; the TTM figure through Dec 2014 stood at 0.06 (down 74.39% YoY), while the FY2014 annual figure was 0.06, down 74.39% from the prior year.
- Debt Ratio fell to 0.06 in Q4 2014 per PVLA's latest filing, from 17.95 in the prior quarter.
- Across five years, Debt Ratio topped out at 17.95 in Q3 2014 and bottomed at 0.06 in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.47 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 0.04 |
| Sep 30, 2025 | 0.03 |
| Jun 30, 2025 | 0.03 |
| Mar 31, 2025 | 0.02 |
| Dec 31, 2024 | 0.02 |
| Dec 31, 2014 | 0.06 |
| Sep 30, 2014 | 17.95 |
| Jun 30, 2014 | 0.09 |
| Mar 31, 2014 | 12.62 |
| Dec 31, 2013 | 0.23 |
| Jun 30, 2013 | 0.09 |